The Latest Breaking News from Eli Lilly

The company behind the drug donanemab said it will ask regulators to reconsider the decision.

Potential US tariffs on pharmaceuticals could set off a ripple effect that extends far beyond the immediate price hikes, as both the US and Europe heavily rely on each other.

See what analysts' price targets say about the prospects of these three stocks flirting with the $1 trillion valuation mark.

The World Health Organization states that there were around 830 million people living with diabetes in 2022. More than half of them weren't taking diabetes medications, including insulin, likely due to access and cost issues.

Eli Lilly's blockbuster drug 'Mounjaro' was launched in India on Thursday. The pharma manufacturer said it has launched a first-of-its-kind medication for obesity and type 2 diabetes in the country after obtaining approval from the Central Drugs Standard Control Organisation (CDSCO). The company said it has introduced Mounjaro in a…

Amgen is hoping to rival Novo Nordisk and Eli Lilly in the weight-loss drug market.

Pharma giant Eli Lilly announced plans to make a massive investment in the United States. What does this and another big announcement mean for Lilly?

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance

Despite Johnson & Johnson’s underperformance relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Eli Lilly has outperformed the Nasdaq over the past year, and analysts are highly optimistic about the stock’s prospects.

Skye Bioscience is trying to establish a presence in the weight-loss drug market.